scispace - formally typeset
Search or ask a question

Showing papers by "Yuan Soon Ho published in 2015"


Journal ArticleDOI
TL;DR: A negative feedback whereby Skp2-mediated RagA ubiquitination recruits GATOR1 to restrict mTORC1 signaling upon sustained amino acid stimulation is proposed, which serves a critical mechanism to maintain proper cellular functions.

70 citations


Journal ArticleDOI
TL;DR: Administration of the local anesthetics bupivacaine or ropavacaine during breast cancer surgery decreased pain significantly at only 2 h but did not reduce pain at 12, and 24 h postoperatively.

45 citations


Journal ArticleDOI
TL;DR: The results suggest that FUCA1 may be a potential prognostic molecular target for clinical use, especially in TNBC patients, as detected by wound healing and invasion assays.
Abstract: α-L-fucosidase 1 (FUCA1) is a lysosomal enzyme that catalyzes the hydrolytic cleavage of the terminal fucose residue in breast cancer cells. FUCA1 mRNA levels were detected by real-time PCR, and there was a greater than 139-fold increase in FUCA1 mRNA expression in breast tumor samples compared with normal breast tissue samples (*P = 0.005, n = 236). Higher FUCA1 mRNA expression was preferentially detected in early-stage tumors (stage 0 to 2) compared with advanced-stage tumors (stage 3 to 4) (stage 0-1 versus stage 3, *P = 0.015; stage 0-1 versus stage 4, *P = 0.024). FUCA1 protein levels were higher in advanced-stage tumors concomitant with decreased fucosylated Lewis-x antigen expression, as evidenced using the immunohistochemical staining H-score method (*P < 0.001). Statistical analysis revealed that lower FUCA1 levels significantly predicted an inferior overall survival rate among triple-negative breast cancer (TNBC) patients compared with non-TNBC patients (*P = 0.009). Two stable FUCA1 siRNA knock-down MDA-MB-231 cell lines were established, and the results suggest that transient FUCA inhibition creates a selective pressure that triggers the metastasis of primary tumor cells, as detected by wound healing and invasion assays (*P < 0.01). The results suggest that FUCA1 may be a potential prognostic molecular target for clinical use, especially in TNBC patients.

33 citations



Patent
04 Aug 2015
TL;DR: In this paper, a drug nanocarrier that is stabilized by lipids, preferably lecithins and/or lipid-terminated polyalkylene glycol, for the delivery of poorly soluble drugs with high drug loading and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis is presented.
Abstract: The present invention relates to generally to pharmaceutical formulations. Particularly, the present invention relates to a drug nanocarrier that is stabilized by lipids, preferably lecithins and/or lipid-terminated polyalkylene glycol, for the delivery of poorly soluble drugs with high drug loading and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

1 citations